GBG logo Molecular Interaction Maps LMP, CCR, NCI, NIH
Genomics and Bioinformatics Group Home
MIM home
STKE Paper
Map Symbols
Map Navigation
The ATM-Chk2 kinase pathway
Map description Static Map Image

The ATM-Chk2 kinase pathway

The best way to view the map is with on a PC with Firefox or Chrome and on a MAC with Safari or Chrome.

ATM-Chk2 kinase pathway
The ATM-Chk2 kinase pathway

The ATM-Chk2 kinase pathway

Yves Pommier, Mirit I. Aladjem and Kurt W. Kohn

Implemented by : Margot Sunshine

To read the original paper describing this map and the symbols used, click
here. This map has been updated since the article was published.

This MIM represents the ATM-Chk2 pathway. This pathway is activated by double strand breaks that are recognized by the phosphorylated histone H2AX and members of the MRN complex. The pathway includes the DNA damage sensor kinases (ATM, ATR and DNA-PK), the adaptor BRCT proteins (Nbs1, Brca1, 53BP1, MDC1) and the effector kinases (Chk2, Chk1, Plk3, JNK, p38). A characteristic of the ATM-Chk2 pathway is its apparent redundancy. For instance, ATM and Chk2 have common substrates including p53, PML, E2F1, BRCA1, and Chk2 itself, suggesting that Chk2 (also known as CHECK2, Cds1 in fission yeast, and Dmchk2 or Dmnk or Loki in the fruit fly) can act as a relay for ATM and/or as a salvage pathway when ATM is inactivated. Some of the same substrates can also be phosphorylated/activated by other pathways than ATM-Chk2, including Chk1, and the polo kinases (Plk�s).

Most anticancer agents presently used clinically target the genome by damaging DNA. Their tumor selectivity is probably due to tumor-specific defects affecting cell cycle checkpoints and DNA repair, and enhancing apoptotic response in the tumor. Functionally, Chk2 can activate both apoptosis (via p53, and PML) and cell cycle arrest at S-phase (via cdc25A and cdc25C, p53, and BRCA1). Chk2 inhibitors can be used to enhance the tumor selectivity of DNA damaging agents in p53-deficient tumors, and for the treatment of tumors with enhanced Chk2 activation.

Map symbols       Map Navigation

This website is a development of the Genomics and Pharmacology Facility, Developmental Therapeutics Branch (DTB), Center for Cancer Research (CCR), National Cancer Institute (NCI).

If you have questions or comments about this site, please send them to:

Genomics and Pharmacology Facility
                Home Page Link to Center for Cancer Research Home Page Link to National Cancer Institute Home Page Link to National Institutes of Health Link to Department of Health & Human Services Home Page